ARS Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-171.3M | $8.0M | $-54.4M | $-34.7M | $-20.2M | $-32.9M |
| Depreciation & Amortization | $1.4M | $79.0K | $100.0K | $319.0K | $213.0K | — |
| Depreciation | — | $79.0K | $73.0K | $34.0K | $783.0K | $637.0K |
| Amortization | $800.0K | $100.0K | — | — | — | — |
| Stock-Based Compensation | $22.1M | $14.5M | $9.2M | $5.8M | $2.8M | $2.6M |
| Net Cash from Operating Activities | $-170.9M | $13.5M | $-59.3M | $-40.1M | $-17.6M | $-31.2M |
| Investing Activities | ||||||
| Capital Expenditures | $339.0K | $563.0K | $175.0K | $199.0K | $55.0K | $917.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $56.8M | $-106.1M | $-87.2M | $-199.0K | $-55.0K | $-917.0K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $104.6M | $72.4M | $6.9M | $190.7M | $53.2M | $408.5M |
| Net Change in Cash | $-9.5M | $-20.2M | $-139.5M | $150.5M | $35.5M | — |
| Free Cash Flow | $-171.2M | $13.0M | $-59.4M | $-40.3M | $-17.6M | $-32.1M |